Revance to Participate in the JMP Securities Life Sciences Conference 2018

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the JMP Securities Life Sciences Conference 2018 in New York, NY.

President and Chief Executive Officer, Dan Browne, is scheduled to participate in a fireside chat on Wednesday, June 20 at 4:00pm ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Revance Therapeutics, Inc.

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, with plans to initiate studies in upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180614005009/en/

INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert, 714-325-3584
[email protected]
or
Burns McClellan, Inc.:
Ami Bavishi, 212-213-0006
[email protected]
or
MEDIA
General Media:
TOGORUN:
Mariann Caprino, 917-242-1087
[email protected]
or
Trade Media:
Nadine Tosk, 504-453-8344
[email protected]

Source: Revance Therapeutics, Inc.

You May Also Be Interested In

• Silver Palace Nominated for gamescom Best Mobile Game Award as New Trailer Debuts at Opening Night Live
• The Nest is Redefining Community for Modern Families in Bergen County
• Top Meme Coin News: Bitcoin’s $80,000 Breakout Fuels PEPE and Floki Rally – Is the Next 100x Meme Coin Here?